Agios
Since our founding, Agios has been a pioneering leader in cellular metabolism, advancing therapies for patients with unmet needs. Our mature and unique understanding of the science is foundational to our success and the connective thread …
About Us - Agios
At Agios, building bonds and cultivating relationships are at the heart of our ability to create life-changing therapies for people with rare diseases. We are a biopharmaceutical company that believes connections unlock potential.
Pipeline - Agios
Agios has a proven track record of leveraging our expertise in cellular metabolism to develop new therapies and bring innovative medicines to patients in need. Building on our core capabilities, we are advancing a robust pipeline focused on rare diseases.
Leadership - Agios
At Agios, leadership means building stronger bonds with colleagues, partners and patient communities and honoring each of their perspectives to make the process of developing life-changing treatments for patients with rare diseases more collaborative, creative and productive.
Investors Overview – Agios Pharmaceuticals, Inc.
2024年10月31日 · The Investor Relations website contains information about Agios Pharmaceuticals, Inc.'s business for stockholders, potential investors, and financial analysts.
History - Agios
For nearly 15 years, Agios has been committed to furthering the science of cellular metabolism to identify therapies for patients with unmet needs. Our deep and differentiated understanding of the science is foundational to our success and the connective thread that binds our people and our pipeline together.
Our Science - Agios
Agios is the pioneer in the science of pyruvate kinase (PK) activation. PK is an enzyme that plays an important role in regulating cell metabolism. It is responsible for the final step in glycolysis in red blood cells, which is required for maintaining red blood cell energy levels and structure.
Agios Announces Phase 3 ENERGIZE Study of Mitapivat Met …
2024年1月3日 · Agios Announces Phase 3 ENERGIZE Study of Mitapivat Met Primary Endpoint and Both Key Secondary Endpoints in Adults with Non-Transfusion-Dependent Alpha- or Beta-Thalassemia. Jan 03, 2024. PDF Version. –Mitapivat Demonstrated a Statistically Significant Increase in Hemoglobin Response Rate Compared to Placebo –.
Agios to Focus on Developing and Commercializing Innovative …
CAMBRIDGE, Mass., Dec. 21, 2020 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that it will move forward with a singular focus on accelerating and expanding its genetically defined disease portfolio, including the mitapivat ...
Our Medicine - Agios
Patient support. Agios offers the myAgios ® patient support services program as a single point of engagement for eligible patients, including access support, prescription fulfillment, financial assistance, disease education and community connections.